FINWIRES · TerminalLIVE
FINWIRES

$FDMT

3 stories mentioning FDMTUpdated just now

Every FINWIRES story that references FDMT, newest first.

What are analysts saying about FDMT?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on FDMT?

Insider Trading

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

David Kirn, Director, President and Chief Executive Officer, on September 14, 2026, sold 58,333 shares in 4D Molecular Therapeutics (FDMT) for $811,004. Following the Form 4 filing with the SEC, Kirn has control over a total of 767,486 common shares of the company, with 767,486 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1650648/000119312526393243/xslF345X05/ownership.xml

$FDMT
Research

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28, according to analysts polled by FactSet.

$FDMT
Research

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28.67, according to analysts polled by FactSet.Price: $10.27, Change: $+0.20, Percent Change: +1.99%

$FDMT

Track with the FINWIRES app suite

FolioX
FolioX
Track FDMT in your portfolio
WheelAI
WheelAI
Analyze FDMT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on FDMT